Evaluating the Use of Monoclonal Antibodies and Antivirals for COVID-19
The Dutch Cohort Study for the Evaluation of the Use of Neutralizing Monoclonal Antibodies and Other Antiviral Agents Against SARS-CoV-2
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · NCT05195060
This study is testing whether monoclonal antibodies and antiviral medications can help treat COVID-19 in patients who are immunocompromised or have low antibody levels.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (other) |
| Drugs / interventions | casirivimab, imdevimab, sotrovimabsotrovimab, balanivimab, sotrovimab, bamlanivimab, etesevimab, sSotrovimab, casivirmimab |
| Locations | 4 sites (Amsterdam, Noord Holland and 3 other locations) |
| Trial ID | NCT05195060 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the effectiveness of neutralizing monoclonal antibodies and antiviral agents in treating COVID-19 patients. It focuses on patients who receive these treatments as standard care, particularly those who are seronegative or immunocompromised. The study will collect data on patient outcomes, including rates of hospitalization and mortality, to assess the impact of these therapies. By analyzing real-world data, the study seeks to provide insights into the best practices for managing COVID-19.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older who are receiving neutralizing monoclonal antibodies or antiviral treatments for COVID-19.
Not a fit: Patients who are not receiving these specific treatments or who cannot provide informed consent may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment protocols for COVID-19, particularly for high-risk patients.
How similar studies have performed: Other studies have shown success with similar approaches, particularly in the use of monoclonal antibodies for COVID-19 treatment.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * All patients that are treated with neutralizing monoclonal SARS-CoV-2 antibodies or with small-molecules for Covid-19 as standard of care. * Patients have to be aged ≥ 18 y. Exclusion Criteria: * No informed consent is provided by the patient or by his/her legal representative * Patients not suitable to fulfil study procedures
Where this trial is running
Amsterdam, Noord Holland and 3 other locations
- Amsterdam University Medical centre - VUMC — Amsterdam, Noord Holland, Netherlands (RECRUITING)
- Amsterdam University Medical Centre — Amsterdam, Noord-Holland, Netherlands (RECRUITING)
- Leiden universitair medisch centrum — Leiden, Netherlands (RECRUITING)
- Radboud Universitair Medisch Centrum — Nijmegen, Netherlands (RECRUITING)
Study contacts
- Study coordinator: Willem Joost Wiersinga, Prof.
- Email: w.j.wiersinga@amsterdamumc.nl
- Phone: +31 20 5669111
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: COVID-19